John Pitts

Dr. John Pitts


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CCChristopher Centeno
Christopher Centeno
JPJohn Pitts
John Pitts
HAHasan Al-Sayegh
Hasan Al-Sayegh
MFMichael Freeman
Michael Freeman
Introduction.We investigated the use of autologous bone marrow concentrate (BMC) with and without an adipose graft, for treatment of knee osteoarthritis (OA).Methods.Treatment registry data for patients who underwent BMC procedures with and without an adipose graft were analyzed. Pre- and posttreatment outcomes of interest included the lower extremity functional scale (LEFS), the numerical pain scale (NPS), and a subjective percentage improvement rating. Multivariate analyses were performed to examine the effects of treatment type adjusting for potential confounding factors. The frequency and type of adverse events (AE) were also examined.Results.840 procedures were performed, 616 without and 224 with adipose graft. The mean LEFS score increased by 7.9 and 9.8 in the two groups (out of 80), respectively, and the mean NPS score decreased from 4 to 2.6 and from 4.3 to 3 in the two groups, respectively. AE rates were 6% and 8.9% in the two groups, respectively. Although pre- and posttreatment improvements were statistically significant, the differences between the groups were not.Conclusion.BMC injections for knee OA showed encouraging outcomes and a low rate of AEs. Addition of an adipose graft to the BMC did not provide a detectible benefit over BMC alone.

1 July 2015 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
JPJohn Pitts
John Pitts
HAHasan Al-Sayegh
Hasan Al-Sayegh
MFMichael D Freeman
Michael D Freeman
CCChristopher J Centeno
Christopher J Centeno
Introduction: This was a prospective case series designed to investigate treatment for anterior cruciate ligament (ACL) tears using an injection of autologous bone marrow concentrate. Methods: Consecutive adult patients presenting to a private outpatient interventional musculoskeletal and pain practice with knee pain, ACL laxity on exam, and magnetic resonance imaging (MRI) evidence of a grade 1, 2, or 3 ACL tears with less than 1 cm retraction were eligible for this study. Eligible patients were treated with an intraligamentous injection of autologous bone marrow concentrate, using fluoroscopic guidance. Pre- and postprocedural sagittal MRI images of the ACLs were analyzed using ImageJ software to objectively quantify changes between pre- and posttreatment scans. Five different types of measurement of ACL pixel intensity were examined as a proxy for ligament integrity. In addition pain visual analog scale (VAS) and Lower Extremity Functional Scale (LEFS) values were recorded at baseline and at 1 month, 3 months, 6 months, and annually postinjection. Objective outcomes measured were pre- to post-MRI measurement changes, as analyzed by the ImageJ software. Subjective outcomes measured were changes in the VAS and LEFS, and a self-rated percentage improvement. Results: Seven of ten patients showed improvement in at least four of five objective measures of ACL integrity in their postprocedure MRIs. In the entire study group, the mean gray value, median, raw integrated density, and modal gray value all decreased toward low-signal ACLs (P=0.01, P=0.02, P=0.002, and P=0.08), indications of improved ligament integrity. Seven of ten patients responded to the self-rated metrics follow up. The mean VAS change was a decrease of 1.7 (P=0.25), the mean LEFS change was an increase of 23.3 (P=0.03), and mean reported improvement was 86.7%. Conclusion: Based on this small case series, autologous bone marrow concentrate shows promise in the treatment of grade 1, 2, and possibly grade 3 ACL tears without retraction. Further investigation using a controlled study design is warranted.

26 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
NHNicholas Hooper
Nicholas Hooper
JIJoseph Angelo Ierulli
Joseph Angelo Ierulli
CDChase Demarest
Chase Demarest
JPJohn Pitts
John Pitts
OOOluseun A. Olufade
Oluseun A. Olufade
CWChristopher Williams
Christopher Williams
Background/Objectives: Low back pain (LBP) remains one of the leading causes of disability globally and contributes significantly to healthcare expenditures. Discogenic LBP, a subtype stemming from intervertebral disc degeneration, often provesrefractory to conventional treatment modalities. Regenerative orthobiologic therapies, including platelet-rich plasma (PRP), platelet lysate (PL), and mesenchymal stem cells (MSCs), have emerged as promising alternatives, though long-term outcomes and safety profiles are not yet well understood. Methods: This case series reports 13 patients treated between 2015 and 2016 at an outpatient interventional pain center who received intradiscal culture-expanded MSC injections with or without additional injections to other surrounding vertebral structures. There was no control group. Inclusion required patients to have discogenic LBP with or without radiculopathy and at least six years of completed follow-up data. Outcomes were assessed using Numeric Rating Scale (NRS), Functional Rating Index (FRI), and modified Single Assessment Numeric Evaluation (SANE) scores at multiple time points up to 10 years post treatment. Results: Thirteen patients met the inclusion criteria. Significant reductions in NRS and FRI scores were observed at 6 months, 3 years, and 6 years (p < 0.01). At 6 years, the average NRS score decreased by 2.50 points, FRI by 24.14 points, and SANE showed a 60% improvement. At 10 years, among the seven patients who responded, average SANE improvement was 78.1%. No adverse events were reported. Conclusions: This study presents the longest known follow-up data for intradiscal MSC therapy for discogenic LBP, demonstrating sustained improvements in pain and function. These findings support further investigation into combination orthobiologic therapies as a viable long-term treatment option for chronic LBP.

15 May 2025 in Cureus
Verified
Journal Article
Open access
PDF file
JPJohn Pitts
John Pitts
JMJason Markle
Jason Markle
DBDustin Berger
Dustin Berger
EDEhren Dodson
Ehren Dodson
Purpose: Cervical discogenic pain is a prevalent and debilitating condition. In recent years, autologous regenerative therapies such as bone marrow concentrate (BMC) and platelet-rich plasma (PRP) have gained attention as potential alternatives to traditional interventional pain management. This study investigates the safety and efficacy of these treatments when delivered intradiscally as part of a comprehensive cervical functional spinal unit (FSU) approach. Methods: This is a retrospective case series utilizing registry data, with 18 participants meeting the inclusion criteria. Intradiscal injections of BMC or leukocyte-rich PRP were guided by ultrasound and fluoroscopy with contrast confirmation. Patient-reported outcome measures (PROMs), including the Functional Rating Index (FRI), Numeric Pain Scale (NPS), and a modified Single Assessment Numeric Evaluation (SANE), were collected at baseline and at a minimum of three months post-treatment, with a mean follow-up of one year. Results: Eleven participants received BMC injections, and seven received leukocyte-rich PRP injections. No adverse events were reported during the study period. Statistical analysis revealed a significant reduction in the NPS in half of the patients (9 of 18) (mean difference = −1.0, P = 0.024), while a majority (14 of 18) reported improvement in FRI scores (mean difference = −10.9, P = 0.015). The average SANE score was 60%, with most patients (14 of 18) reporting 50% or greater improvement. Conclusion: Intradiscal injections of BMC or LR-PRP as part of a comprehensive cervical FSU approach appear to be safe and effective for improving patient-reported pain and function. These findings support the potential of autologous biologics as an alternative treatment modality for cervical discogenic pain.

23 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
PGPaulina Giacomelli
Paulina Giacomelli
BMBrendan Martin
Brendan Martin
JMJason Markle
Jason Markle
CWChristopher Williams
Christopher Williams
NHNicholas Hooper
Nicholas Hooper
JPJohn Pitts
John Pitts
Background/Objectives: Platelet-rich plasma (PRP) preparations vary widely, and most studies report concentration rather than absolute platelet dose, limiting cross-study comparison. This review provides an evidence-informed synthesis of platelet dose, concentration, and injectate volume in knee, hip, and glenohumeral osteoarthritis (OA). Methods: A PubMed-based narrative review included 26 primary studies (16 knee, nine hip, and one glenohumeral); systematic reviews provided context. Dose was classified as directly reported, calculated from measured product characteristics, nominally estimated, or assumption-dependent/unverifiable. Assumption-dependent values were excluded from numerical ranges. Randomized trials were assessed with the Cochrane Risk of Bias 2 tool. Results: Knee OA provided the strongest dose-related evidence. Reported, calculated, or aggregate study-level dose estimates ranged from approximately 2.5 to 13.7 billion platelets per injection, with findings suggesting a dose-related signal at approximately 5 billion platelets or greater. In hip OA, measured protocols associated with clinical improvement delivered approximately 6.2–7.0 billion platelets per injection. Glenohumeral evidence was limited to one trial. However, overall, the available evidence did not establish validated minimum or optimal dose thresholds. Conclusions: In knee OA, the available literature shows a dose-related signal at approximately 5 billion platelets or greater per injection, while hip studies report measured protocols around 6–7 billion platelets per injection. These findings are descriptive rather than prescriptive and do not establish clinical dosing thresholds or recommendations. Glenohumeral evidence remains insufficient for dose-specific conclusions.

6 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
NHNicholas Hooper
Nicholas Hooper
AAAhmad Alhusen
Ahmad Alhusen
HSHinnah Siddiqui
Hinnah Siddiqui
JPJohn Pitts
John Pitts
PJPrathap Jayaram
Prathap Jayaram
CWChristopher Williams
Christopher Williams
Background/Objectives: Rotator cuff tears (RCTs) are a leading cause of shoulder pain and disability. Management typically involves conservative measures, such as physical therapy and anti-inflammatory medications, or surgery for full-thickness or refractory tears. Regenerative medicine therapies, including platelet-rich plasma (PRP), platelet lysate (PL), and mesenchymal stem cells (MSCs), show promise as alternative treatment strategies, although long-term outcomes remain under investigation. Methods: This cohort included 30 patients with partial rotator cuff tears and were treated with culture-expanded MSC injections. There was no control group. Inclusion criteria included an imaging-confirmed diagnosis of partial-thickness rotator cuff tears. Outcomes were assessed at multiple time points up to 6 years. Pain and function were assessed using the Disabilities of the Arm, Shoulder, and Hand (DASH), a Numeric Rating Scale (NRS), and the modified Single Assessment Numeric Evaluation (SANE). Results: Thirty patients (37 shoulders) were included in the analysis. Significant improvements in the NRS and DASH scores were observed at 3, 6, 12, 18, and 24 months (p < 0.01). Twenty-four months post-treatment, the mean NRS and DASH decreased by 2.25 and 15.93 points, respectively, and SANE improved by 60%. At six years, among seven respondents, the mean SANE improvement was 75.54%. During this study, no significant adverse events were reported. Conclusions: This study provides the longest known follow-up of MSC therapy for partial-thickness RCTs, finding sustained pain and functional improvements. The findings support further research into MSC-based and combination regenerative therapies as a viable alternative treatment option for partial-thickness rotator cuff tears.